Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting
Ocuphire Pharma (Nasdaq: OCUP) announced the acceptance of six posters featuring its products Nyxol® and APX3330 at the American Academy of Optometry (AAOPT) 2022 Annual Meeting from October 26-29, 2022, in San Diego, CA.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ocuphire Pharma (Nasdaq: OCUP) announced the acceptance of six posters featuring its products Nyxol® and APX3330 at the American Academy of Optometry (AAOPT) 2022 Annual Meeting from October 26-29, 2022, in San Diego, CA. The posters include important findings from clinical trials such as the safety of Phentolamine Ophthalmic Solution and APX3330 for treating eye disorders. The team will present data on various trials, including MIRA Phase 3 and ZETA-1 Phase 2b, showcasing advancements in the treatment of mydriasis and diabetic retinopathy.
Positive
- Acceptance of six posters at AAOPT 2022 showcases research credibility.
- Presentation of data from vital clinical trials may attract investor interest.
Negative
- None.
Details
News Market Reaction – OCUP
The recorded move for OCUP in the trading session of this news was -1.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FARMINGTON HILLS, Mich., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced acceptance and presentation of six posters featuring Nyxol® and APX3330 at the American Academy of Optometry (AAOPT) 2022 Annual Meeting being held October 26-29, 2022 in San Diego, CA.
| AAOPT 2022: San Diego Convention Center | |
| Title: | Safety and Tolerability of Phentolamine Ophthalmic Solution for Reversal of Mydriasis in Two MIRA Phase 3 Trials |
| Poster #: | 260, Exhibit Hall H |
| Date/Time: | Thursday, October 27, 2022, 4:30 PM – 6:30 PM PT |
| Presenter: | Justin Schweitzer, OD |
| Title: | Masked Safety of Oral Drug Candidate APX3330 for the Treatment of Diabetic Retinopathy in an Ongoing ZETA-1 Phase 2b Clinical Trial |
| Poster #: | 200, Exhibit Hall H |
| Date/Time: | Thursday, October 27, 2022, 4:30 PM – 6:30 PM PT |
| Presenter: | Doug Devries, OD |
| Title: | Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal MIRA Phase 3 Trials |
| Poster #: | 188, Exhibit Hall H |
| Date/Time: | Friday, October 28, 2022, 1:00 PM – 3:00 PM PT |
| Presenter: | Leslie O'Dell, OD |
| Title: | MIRA-4, Clinical Trial Evaluating the Safety and Efficacy of Phentolamine Ophthalmic Solution for Reversal of Pharmacologically Induced Mydriasis in Pediatric Subjects Aged 3-11 Years |
| Poster #: | 187, Exhibit Hall H |
| Date/Time: | Friday, October 28, 2022, 1:00 PM – 3:00 PM PT |
| Presenter: | Shane Foster, OD |
| Title: | Phentolamine Alone and in Combination with Low Dose Pilocarpine Improves Near Vision in Presbyopic Subjects in the VEGA-1 Phase 2 Trial |
| Poster #: | 186, Exhibit Hall H |
| Date/Time: | Friday, October 28, 2022, 1:00 PM – 3:00 PM PT |
| Presenter: | Mitch Ibach, OD |
| Title: | LYNX-1: A Pivotal Phase 3 Randomized Placebo-Controlled Trial of Phentolamine Ophthalmic Solution in Subjects with Dim Light Vision Disturbance |
| Poster #: | 185, Exhibit Hall H |
| Date/Time: | Friday, October 28, 2022, 1:00 PM – 3:00 PM PT |
| Presenter: | Shane Kannarr, OD |
About Ocuphire Pharma
Ocuphire is a publicly traded (Nasdaq: OCUP), clinical-stage, ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of refractive and retinal eye disorders. For more information about Ocuphire’s clinical trials, visit https://www.ocuphire.com/clinical-trials.
Ocuphire Contacts
Mina Sooch, President & CEO
Ocuphire Pharma, Inc.
ir@ocuphire.com
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
Bret Shapiro
Core IR
brets@coreir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.